400,000
Participants
Start Date
August 15, 2025
Primary Completion Date
December 30, 2030
Study Completion Date
December 30, 2032
Diagnostic Evaluation for Positive AI Findings
MDT will review positive AI findings (including PDAC, pancreatic precursor lesions and benign lesion) cases to determine next steps: (1) Suspected PDAC and pancreatic precursor lesions are referred for hospital examination with diagnostic results collected; (2) Benign lesion cases receive personalized monitoring until endpoint events or study end; (3) Cases with positive AI findings but MDT-confirmed normal pancreatic issues receive at least one year of follow-up. If any abnormal results arise, management will transition to either plan (1) or (2).
RECRUITING
Meinian Onehealth Healthcare Holdings Co., Ltd, Shanghai
RECRUITING
Ruici Medical Examination Institution, Shanghai
RECRUITING
Changhai Hospital, Shanghai
RECRUITING
Jiaxing University Affiliated Second Hospital, Jiaxing
RECRUITING
Ningbo University Affiliated People's Hospital, Ningbo
Ningbo University Affiliated People's Hospital
UNKNOWN
Jiaxing University Affiliated Second Hospital
UNKNOWN
Meinian Onehealth Healthcare Holdings Co., Ltd
UNKNOWN
Ruici Medical Examination Institution
UNKNOWN
Changhai Hospital
OTHER